Case Study: Practical Strategies for Choosing among Incretin-Based Agents in Type 2 Diabetes, PART 3
Given that Mark is already obese and has gained more weight since commencing glimepiride, and given Mark's worrying episodes of hypoglycemia, you decide to stop glimepiride and commence a GLP-1 receptor agonist....
GLP-1 Knowledge Survey, Part VI
This week we finish our analysis of our GLP-1 survey results with a look at prescribing reasons and habits, and how your colleagues decide on GLP-1 analog or DPP-4 inhibitor therapy. Most of the respondents favored Victoza but...
GLP-1 Special Series Issue #8 Editor's Note
If you do enough interviews you are bound to get a few great ones. Often when we talk to researchers they either hold back on information that they are afraid to share or they try to be experts on everything we ask them. Our publisher, Steve...
Interview with David D'Alessio, MD; Internal Medicine-Endocrinology, Professor
What are the effects of using a GLP-1 drug when on the Atkins diet and a low-fat...
GLP-1 Knowledge Survey Part V
Over the past few weeks we have been looking at your colleagues' responses to questions about GLP-1, including mechanisms, interactions, dosing and effectiveness. Over the next two weeks we will examine some of your opinions on starting doses...
GLP-1 Knowledge Survey Part III
This week we examine more of your responses regarding GLP-1 therapy....
GLP-1 Knowledge Survey Part II
We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered....
